Return to CAP Home
Printable Version

  Table 2: HPV testing—ASCCP 2006 consensus
  guidelines highlights

title

 

 

 

November 2007
PAP/NGC Programs Review

Teresa M. Darragh, MD
Terence J. Colgan, MD

  • Use only analytically and clinically validated HPV tests.
  • Test for high-risk HPV types only. There is no role for low-risk-HPV testing in a cervical cancer screening program.
  • Screening can use co-testing with Pap and HPV in women over 30 years. If both tests are negative, re-screen in three years.
  • HPV testing of adolescents is unacceptable.
  • Reflex HPV testing for the triage of women with ASC-US is preferred, except in women 20 years of age or younger.
  • Reflex HPV testing for the triage of postmenopausal women with LSIL is an acceptable choice.
  • HPV testing may be used as a stand-alone test in the post-colposcopy and post-treatment management guidelines.
  • Use HPV testing in the post-colposcopy management of low-grade abnormalities at 12-month intervals.
  • Use HPV testing in the post-treatment management of HSIL and AIS at six- to 12-month intervals as test of cure.

Dr. Darragh, a member of the CAP Cytopathology Committee, is professor of clinical pathology, Departments of Pathology and Ob/Gyn, University of California San Francisco/Mt. Zion Medical Center, San Francisco. Dr. Colgan, a former member of the Cytopathology Committee, is chief, gynecologic pathology, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, and professor, University of Toronto.
 

Related Links